



+++
ENVIGO

Research Models
and Services

Inbred Rats

WF (Wistar Furth)

Origin

Developed by Furth in 1945 from a commercial Wistar stock, in an attempt to develop a strain with high incidence of leukemia. In 1975, to National Institutes of Health, Bethesda, Maryland.

WF/NHsd

Harlan Laboratories, Inc., obtained a breeding nucleus from National Institutes of Health. Harlan became Envigo in 2015.

Characteristics

Leukemia, characterized by an unusual type of mononuclear cell containing distinct reddish granules, occurred in 15.8-22% of old rats. Mean life-span 23 months in males and 21 months in females. High incidence of pituitary tumors. WF rats develop retinal dystrophy from about three months of age (Lin and Essner, 1988). Low serum growth hormone (Esber *et al*, 1974). Low blood pressure, reaching 123 mmHg at 10 weeks of age (Tanase *et al*, 1982). Low antibody response to streptococcal group A carbohydrate; not linked to RT1 (Stankus and Leslie, 1976). Resistant to the development of experimental autoimmune myasthenia gravis (Biesecker and Koffler, 1988). Grafts of aorta from DA develop arteriosclerotic changes in the vascular wall (Mennander *et al*, 1992). Resistant to the development of 4-nitroquinoline 1-oxide induced squamous cell carcinomas of the tongue. (Kitano *et al*, 1992).

Characteristics of the WF strain have been described by Festing (1979) and Greenhouse *et al* (1990).

Genetics

Coat color genes - a, B, c, h : albino.

Histocompatibility - RT1^u, RT2^b, RT3^b, RT8^b.

Biochemical markers - Acon-1^a, Acp-2^a, Ahd-2^a, Akp-1^a, Alb^a, Amyl^a, Cryg-1^a, Es-1^a, Es-2^c, Es-3^c, Es-4^b, Es-6^b, Es-7^b, Es-8^a, Es-9^c, Es-10^b, Es-14^b, Es-15^b, Es-16^b, Es-18^a, Fh-1^b, Gc^a, Glo-1^b, Gox-1^a, Hbb^a, Igk-1^a, Lap-1^a, Mgd-1^b, Pep-3^a, Pg-1^a, Pgd^b.

This strain carries a distinctive heteropyknotic Y chromosome that can be used as a cellular marker (Zieverink and Moloney, 1965).

References

1. Bender K, et al. (1994) Genetic characterization of inbred strains of the rat (*Rattus norvegicus*). *J. Exp. Anim. Sci.* 36, 151-165.
2. Biesecker G and Koffler D (1988) Resistance to experimental autoimmune myasthenia gravis in genetically inbred rats. *J. Immunol.* 140, 3406-3410.
3. Esber HJ, Menniger FF Jr and Bogdon AE (1974) Variation in serum hormone concentrations in different rat strains. *Proc. Soc. Exp. Biol. Med.* 146, 1050-1053.
4. Festing MFW (1979) Inbred strains. In: *The Laboratory Rat. Vol. I. Biology and Diseases* (Baker HJ, Lindsey JR and Weisbroth SH, eds). New York: Academic Press, pp 55-72.
5. Greenhouse DD, Festing MFW, Hasan S and Cohen AL (1990) Catalogue of inbred strains of rats. In: *Genetic monitoring of inbred strains of rats* (Hedrich HJ, ed). Stuttgart, New York: Gustav Fischer Verlag, pp. 410-480.
6. Kitano H, Hatano H and Shisa H (1992) Strain difference of susceptibility to 4-nitroquinoline 1-oxide-induced tongue carcinoma in rats. *Jpn. J. Cancer Res.* 83, 843-850.
7. Lin W-L and Essner E (1988) Retinal dystrophy in Wistar-Furth rats. *Exp. Eye Res.* 46, 1-12.
8. Moloney WC, Boschetti AE and King V (1969) Observations on leukemia in Wistar Furth rats. *Cancer Res.* 29, 938-946.
9. Molteni A, Nickerson PA, Gallant S and Brownie AC (1975) Resistance of W/Fu rats to adrenal regeneration hypertension. *Proc. Soc. Exp. Biol. Med.* 150, 80-84.
10. Mennander A, Tiisala S, Ustinov J, Raisanen A, Paavonen T and Hayry P (1992) Chronic rejection of rat aortic allografts. 3. Synthesis of major eicosanoids by vascular wall components and effect of inhibition of the thromboxane cascade. *Arteriosclerosis and Thrombosis* 12, 1380-1386.
11. Stankus RP and Leslie GA (1976) Rat interstrain antibody response and crossidiotypic specificity. *Immunogenetics* 3, 65-73.
12. Tanase H, Yamori Y, Hansen CT and Lovenberg H (1982) Heart size in inbred strains of rats. Part I. Genetic determination of the development of cardiovascular enlargement in rats. *Hypertension* 4, 846-872.
13. Zieverink WD and Moloney WC (1965) Use of the Y chromosome in the Wistar/Furth rat as a cellular marker. *Proc. Soc. Exp. Biol. Med.* 119, 370-373.

Contact us

North America 800.793.7287 EU and Asia envigo.com/contactus info@envigo.com



Envigo RMS Division, 8520 Allison Pointe Blvd., Suite 400, Indianapolis, IN 46250, United States